First Targeted Cancer Drug Focused on Mutation Rather than Tumor Type is Approved
December 5, 2018
The United States food and Drug Administration (FDA) has just approved a new targeted cancer drug known as larotrectinib. This innovative new therapy is the first of its kind to act on a specific gene mutation in a tumor, TRK fusion, disregarding where the cancer had originated.
The therapy has been approved for tumors which have spread throughout the body or those which cannot be removed by surgical means. Additionally, it has been approved for individuals who have no other possible treatment options or those whose cancers have progressed following other treatments.
This drug has revealed just some of the possible potential of precision oncology as it can be utilized against numerous forms of cancer rather than just a specific tumor location.